Particle.news

Spain Pilots Selective Prostate Screening to Reduce Unnecessary Biopsies

The Praise‑U trial routes men through PSA, prostate‑volume measurement and PSA density before using multiparametric MRI and targeted biopsy to find cancers that need treatment.

Overview

  • The Praise‑U pilot in Catalonia and Galicia tests a stepwise screening cascade that starts with a PSA blood test and uses prostate volume by ultrasound to calculate PSA density before ordering mpMRI and biopsy.
  • The trial's PSA threshold is 3 ng/ml and it only refers men for mpMRI when PSA density exceeds 10 ng/cm2, a strategy meant to lower detection of slow, clinically insignificant tumors.
  • Spanish clinicians reported participation around 43% in one centre and said the approach can identify clinically relevant cancers while reducing unnecessary biopsies, but they warn limited mpMRI and biopsy capacity could constrain scaling.
  • Experts continue to recommend starting routine PSA checks around age 50 and earlier for men with first‑degree relatives or known genetic risk, and they stress active surveillance for many low‑risk tumors to avoid overtreatment.
  • Wider adoption will depend on tackling access gaps, public education to overcome stigma and health‑system investment in imaging and biopsy pathways so more men can benefit from early, targeted detection.